Clinical trials: Urinary Symptoms
Overactive Bladder (OAB), Pharmacokinetics of Mirabegron
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
The purpose of this study was to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluated the safety and tolerability of mirabegron in pediatric participants with OAB and…
- Trial name
- Dolphin (NCT04641975)
- Testing
- Mirabegron
- Where
- 15 sites in Belgium, France and 8 more
- Volunteers
- 26 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Overactive Bladder, Urinary Incontinence
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.
- Trial name
- NCT01767519
- Testing
- BOTOX®, solifenacin
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 356 people
- Sponsor
- Allergan
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
MCS in the Treatment of Lower Urinary Tract Symptoms
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
- Trial name
- MCS_LUTS (NCT01002417)
- Testing
- MCS-2 15 mg/day, MCS-2 30 mg/day
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Catheter-Associated Infection
Clinical Evaluation of Copesilcup
Healthcare-associated infections (HAIs): HAIs are a problem for all institutions and countries worldwide. Currently, one of the main infections is catheter-associated urinary tract infection (CAUTI).
- Trial name
- Copesilcup (NCT07530328)
- Testing
- PEGylated Silicone Urinary Catheter with Copper Nanoparticles (COPESILCUP), Control Device
- Where
- Chile
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- WMAS SpA
Stress Urinary Incontinence
A Feasibility Study With a Novel, Dynamic and Disposable Over-the-counter Device for Stress Urinary Incontinence
This study was designed as an open label, feasibility, single-center, cross-over prospective study in women with stress urinary incontinence. Subjects served as their own control.
- Trial name
- NCT04325477
- Testing
- Nolix Device
- Where
- Israel
- Volunteers
- 26 people
- Sponsor
- Gynamics LTD
Stress Urinary Incontinence
To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence
This is an on-going study to evaluate the long-term safety and maintenance of effect of duloxetine in patients suffering with stress urinary incontinence.
- Trial name
- NCT00190632
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Stress Urinary Incontinence, Intrinsic Sphincter Deficiency
Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence
The pre-pubic approach of the tension free vaginal sling placement is a new approach in the treatment of SUI. The retropubic approach of the tension free vaginal sling is the standard method of device delivery; in addition a…
- Trial name
- NCT00688298
- Testing
- Prefyx PPS™ System, Advantage ™ System
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Overactive Bladder (OAB)
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
This study will evaluate safety, efficacy and patient's perception of outcome after treatment with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in patients with OAB who are dissatisfied with…
- Trial name
- NCT00366002
- Testing
- Darifenacin
- Where
- 82 sites in United States
- Volunteers
- 500 people
- Sponsor
- Novartis
Heart Failure, Overactive Bladder
Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
This research study is being done to compare the effectiveness two drugs: an Extended Release Torsemide (ERT) versus generic Immediate Release Torsemide (IRT) in reducing the worsening of symptoms of Overactive Bladder (OAB…
- Conditions
- Heart Failure, Overactive Bladder, Incontinence
- Trial name
- NCT06206512
- Testing
- Extended release torsemide, Immediate release torsemide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Multiple Sclerosis, Neurogenic Bladder
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis
- Conditions
- Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases
- Trial name
- SONIC (NCT00629642)
- Testing
- Solifenacin Succinate, Oxybutynin Hydrochloride
- Where
- 39 sites in Australia, Belgium and 9 more
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
This Phase 3 trial will investigate the efficacy, tolerability and safety of fesoterodine fumarate (SR) (fesoterodine; SPM 907) in adult male and female subjects with overactive bladder syndrome.
- Trial name
- NCT00138723
- Testing
- SPM 907
- Sponsor
- Pfizer
Benign Prostatic Hyperplasia
A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)
Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control.
- Trial name
- NCT07619105
- Testing
- Vesomni
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Korea, Inc.
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Stress Urinary Incontinence, Vulvovaginal Signs and Symptoms
Clinical Evaluation of Fractional Bi-Polar RF for Symptoms of SUI and Vulvovaginal Atrophy
Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Stress Urinary Incontinence and Vulvovaginal Atrophy
- Trial name
- NCT04705571
- Testing
- MorpheusV Applicator
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- InMode MD Ltd.
Urinary Incontinence, Stress
Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)
Validation of a new Quality of Life (QoL) questionnaire in a population of patient gaining a TiLOOP® TAPE surgical mesh for stabilization of the urethra.
- Trial name
- NCT01358214
- Testing
- Questionnaire on Quality of Life.
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- pfm medical gmbh
Benign Prostatic Hyperplasia, BPH
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Conditions
- Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
- Trial name
- NCT01846793
- Testing
- NX-1207
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- Nymox Corporation
Urinary Disorders, Urinary Incontinence
Study Evaluating the Ability of a NIRS Module to Detect a Urodynamic Variation in Humans (DETTECH)
NIRS technology is therefore a technique that exploits the different absorption properties of oxygenated and deoxygenated hemoglobin to evaluate the degree of tissue oxygenation.
- Conditions
- Urinary Disorders, Urinary Incontinence, Urinary Bladder Diseases
- Trial name
- DETTECH (NCT04161716)
- Testing
- NIRS recording
- Where
- France
- Volunteers
- 40 people
- Sponsor
- BioSerenity
Benign Prostatic Hyperplasia
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT00284518
- Testing
- botulinum toxin Type A, normal saline
- Where
- 11 sites in Australia, Austria and 9 more
- Volunteers
- 380 people
- Sponsor
- Allergan
Urinary Lithiasis
Evaluation of the Safety and Performance of the Hydrustent® Biodegradable Hydrogel Ureteral Stent
The goal of this clinical investigation is to evaluate whether the Hydrustent® medical device is safe and if maintain the urinary flow inside the ureter in adults.
- Trial name
- Hydrustent (NCT06719089)
- Testing
- Biodegradable double loop ureteral stent, PolyUrethane Double Loop Ureteral Stent
- Where
- 4 sites in Portugal
- Volunteers
- 134 people
- Sponsor
- Hydrumedical